ArticleExpert opinion on orphan drugs2016
Tissue Chips to aid drug development and modeling for rare diseases.
Article in Expert opinion on orphan drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Microgravity Therapy as Treatment for Decelerated Aging and Successful Longevity.International journal of molecular sciences · 2025Review
- Organs in orbit: how tissue chip technology benefits from microgravity, a perspective.Frontiers in lab on a chip technologies · 2024Article
- Recent Advances in Organ-on-Chips Integrated with Bioprinting Technologies for Drug Screening.Advanced healthcare materials · 2023Review
- Building Blood Vessel Chips with Enhanced Physiological Relevance.Advanced materials technologies · 2023Article
- Blood-brain-barrier modeling with tissue chips for research applications in space and on Earth.Frontiers in space technologies · 2023Article
- The Modular µSiM: A Mass Produced, Rapidly Assembled, and Reconfigurable Platform for the Study of Barrier Tissue Models In Vitro.Advanced healthcare materials · 2022Article
- A proof-of-concept study poised to remodel the drug development process: Liver-Chip solutions for lead optimization and predictive toxicology.Frontiers in medical technology · 2022Article
- Development of a Hybrid Polymer-Based Microfluidic Platform for Culturing Hepatocytes towards Liver-on-a-Chip Applications.Polymers · 2021Article
- Microphysiological systems: What it takes for community adoption.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Organs-on-chips: into the next decade.Nature reviews. Drug discovery · 2021Review
- Review
- Potential of Drug Efficacy Evaluation in Lung and Kidney Cancer Models Using Organ-on-a-Chip Technology.Micromachines · 2021Review
- Organ-on-a-Chip: A New Paradigm for Drug Development.Trends in pharmacological sciences · 2021Review
- Trends in the development of human stem cell-based non-animal drug testing models.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2020Review
- Microphysiological Systems: A Pathologist's Perspective.Veterinary pathology · 2020Article
- Article
- Tissue chips - innovative tools for drug development and disease modeling.Lab on a chip · 2017Review
- Microphysiological Systems ("Organs-on-Chips") for Drug Efficacy and Toxicity Testing.Clinical and translational science · 2017Article
- Deep Learning for Drug Discovery and Cancer Research: Automated Analysis of Vascularization Images.IEEE/ACM transactions on computational biology and bioinformaticsArticle
- Organ-on-a-chip as a next-generation tool in drug development: A bibliometric and patent analysis.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe technologies used to design, create and use microphysiological systems (MPS, "tissue chips" or "organs-on-chips") have progressed rapidly in the last 5 years, and validation studies of the functional relevance of these platforms to human physiology, and response to drugs for individual model organ systems, are well underway. These studies are paving the way for integrated multi-organ systems that can model diseases and predict drug efficacy and toxicology of multiple organs in real-time, improving the potential for diagnostics and development of novel treatments of rare diseases in the future. AREAS COVERED: This review will briefly summarize the current state of tissue chip research and highlight model systems where these microfabricated (or bioengineered) devices are already being used to screen therapeutics, model disease states, and provide potential treatments in addition to helping elucidate the basic molecular and cellular phenotypes of rare diseases. EXPERT OPINION: Microphysiological systems hold great promise and potential for modeling rare disorders, as well as for their potential use to enhance the predictive power of new drug therapeutics, plus potentially increase the statistical power of clinical trials while removing the inherent risks of these trials in rare disease populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.